Purchase this article with an account.
Ricardo Barros-Pereira, Raquel Costa, Manuel Falcão, Luis Mendonça, Sofia Fonseca, Rita Gonçalves, Conceição Gonçalves, F. Falcão-Reis, Raquel Soares, Angela Carneiro; Plasma Levels Of Vascular Endothelial Growth Factor Before And After Intravitreal Injection Of Bevacizumab Or Ranibizumab In The Treatment Of Neovascular Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2319.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the vascular endothelial growth factor (VEGF) plasma levels in exudative age-related macular degeneration (AMD) patients before and after intravitreal injections of ranibizumab or bevacizumab and to compare them with age-matched controls.
We studied forty-three exudative AMD patients and nineteen age-matched control patients. Nineteen patients were treated with intravitreal ranibizumab and twenty-four with intravitreal bevacizumab. Blood samples were collected in both groups just before the injections and 28 days after the loading dose. VEGF plasma levels were measured by ELISA.
The mean pre-treatment VEGF concentrations were significantly lower (p=0.05 for each group) in the control groups (162. 85 pg/ml) than in both the bevacizumab (243.63 pg/ml) and in ranibizumab groups (240.89 pg/ml). There was also a significant reduction in VEGF plasma levels twenty-eight days after the loading dose in bevacizumab-treated patients (p=0.00006); the mean reduction that did also occur at this time in the ranibizumab group did not achieve statistical significance (p=0.119). VEGF plasma levels after treatment in the bevacizumab group were similar to the controls (p=0.106).
We found a significant reduction in VEGF plasma levels during the first 28 days after intravitreal bevacizumab injection in exudative AMD patients. Intravitreal Ranibizumab also accomplished VEGF reduction at the same time-point, but not to a level of statistical significance. This difference between intravitreal administration of the two drugs may render disctinct systemic safety profiles.
This PDF is available to Subscribers Only